Colon Cancer: a new therapeutic breakthrough?

Colorectal cancer (CRC) ranks among the most common and deadly cancers worldwide. Despite therapeutic advances, particularly through the combination of surgery and chemotherapy, two major challenges persist: treatment resistance and tumor recurrence. Addressing these limitations, an innovative strategy has emerged: combining the inhibition of O-GlcNAcylation, a key post-translational modification, with reduced doses of chemotherapy. The goal? To redirect cancer cell responses toward apoptosis, a process that promotes their elimination, rather than senescence, which fosters relapse and cancer progression.  

This study investigates whether O-GlcNAcylation inhibition can enhance the efficacy and safety of colorectal cancer treatments.  

O-GlcNAcylation inhibition: a promising strategy to redirect colorectal cancer treatments?  

To evaluate this approach, researchers studied two complementary models: colorectal cancer cell lines (HCT116 and LS174T) and organoids derived from human tumors. The cells were exposed to subtoxic doses of SN38, an active metabolite of irinotecan, in combination with specific O-GlcNAcylation inhibitors (e.g., OSMI-4).  

Key Point: Irinotecan is an anticancer drug primarily used in colorectal cancer treatment, often in combination with other chemotherapeutic agents. It belongs to the class of topoisomerase I inhibitors, a key enzyme involved in DNA replication and transcription.  

The study focused on key criteria to assess the efficacy of this approach, including markers of apoptosis and senescence.

Results show that senescence induced by SN38 is associated with a decrease in O-GlcNAcylation levels. Notably, O-GlcNAcylation inhibition leads to a significant increase in DNA damage and a cellular response shift from senescence to apoptosis, thereby promoting the elimination of tumor cells. Finally, tests on patient-derived organoids confirm the specificity and efficacy of this strategy on cancer cells, with no major toxic effects on healthy tissues, highlighting its potential for clinical applications.  

O-GlcNAcylation inhibition: an innovative approach to transform colorectal cancer treatment  

This study opens major avenues for optimizing colorectal cancer treatment. Using O-GlcNAcylation inhibitors combined with reduced doses of chemotherapy not only minimizes side effects associated with conventional treatments but also lowers the risk of recurrence by eliminating senescent cells through apoptosis. These findings encourage broader clinical applications to validate this strategy and explore potential synergy with other inhibitors targeting cellular metabolism. This personalized approach could revolutionize current therapeutic strategies by enhancing treatment efficacy and specificity while improving patient survival outcomes.